Mark Ragosa - 16 Mar 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol: KNSA
Transactions as of: 16 Mar 2023
Net transactions value: -$9,984
Form type: 4
Filing time: 20 Mar 2023, 17:14:38 UTC
Previous filing: 06 Sep 2022
Next filing: 03 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+872	+11%		8,543	16 Mar 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	$2,934	-256	-3%	$11.46	8,287	16 Mar 2023	Direct
transaction	KNSA	Class A Common Share	Options Exercise		+2,158	+26%		10,445	20 Mar 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	$7,050	-634	-6.1%	$11.12	9,811	20 Mar 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-872	-33%	$0.000000	1,744	16 Mar 2023	Class A Common Share	872		Direct	F1, F2
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-2,158	-100%	$0.000000^*	0	20 Mar 2023	Class A Common Share	2,158		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.
F3	The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs.